Cargando…

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition

Detalles Bibliográficos
Autor principal:	Soweid, Assaad M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774079/ https://www.ncbi.nlm.nih.gov/pubmed/29387696 http://dx.doi.org/10.4103/eus.eus_66_17

Ejemplares similares

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented
por: Iordache, Sevastiţa, et al.
Publicado: (2017)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
por: D’Onofrio, Mirko, et al.
Publicado: (2017)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
por: Sulciner, Megan L., et al.
Publicado: (2022)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Erratum: The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
Publicado: (2018)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
por: Sakaguchi, Tatsuma, et al.
Publicado: (2020)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
por: Vernuccio, Federica, et al.
Publicado: (2021)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, introduction
por: Dietrich, Christoph F.
Publicado: (2017)

The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, FNA pros
por: Petrone, Maria Chiara, et al.
Publicado: (2017)

Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus on the 2017 Definition of Borderline Resectable Cancer
por: Hayasaki, Aoi, et al.
Publicado: (2018)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
por: Barcellini, Amelia, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor
por: Pedrazzoli, Sergio
Publicado: (2023)

Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?
por: Crippa, Stefano, et al.
Publicado: (2017)

The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective
por: Peretti, Umberto, et al.
Publicado: (2017)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma
por: Duconseil, Pauline, et al.
Publicado: (2019)

Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation
por: Papoulas, Michail, et al.
Publicado: (2018)

Advances in the management of pancreatic ductal adenocarcinoma
por: O’Kane, Grainne M., et al.
Publicado: (2021)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Anderson, Eric M., et al.
Publicado: (2021)

High Endothelial Venules and Pancreatic Ductal Adenocarcinoma: A potential game changer
por: Chai, Shu Ming, et al.
Publicado: (2018)

The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold
por: Rubin, Samuel J. S., et al.
Publicado: (2022)

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
por: Crocenzi, Todd, et al.
Publicado: (2016)

Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
por: Secanella, Luis, et al.
Publicado: (2022)

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
por: Chouari, Tarak, et al.
Publicado: (2023)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r2cnftnjr9gso8dbuh0fg4p9gc